Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

Abstract Background Blinatumomab is a BiTE® immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). Aims To assess the efficacy and safety of blinatumomab as first salvage versus second or later salv...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Max S. Topp, Anthony S. Stein, Nicola Gökbuget, Heinz‐August Horst, Nicolas Boissel, Giovanni Martinelli, Hagop Kantarjian, Monika Brüggemann, Yuqi Chen, Gerhard Zugmaier
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2021-04-01
Edice:	Cancer Medicine
Témata:	acute lymphoblastic leukemia BiTE® blinatumomab salvage stem cell transplant
On-line přístup:	https://doi.org/10.1002/cam4.3731
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!